– Total Revenues Increase 15%, with Growth Across All Three Categories –
HARBIN, CHINA, May 21, 2014 — Yew Bio-Pharm Group, Inc. (“Yew Bio” or the “Company”) (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine and products made from yew timber in China, today reported financial results for the three- months ended March 31, 2014.
2014 First Quarter Results
|Three Months Ended March 31,||Percentage|
|TCM Raw Materials||$1,043,980||$896,161||16.5%|
Total revenues for the first quarter of 2014 increased 15.0% to $2.1 million from $1.8 million a year ago. Sales of TCM raw materials amounted to 50.5% of total revenues; sales of yew trees amounted to 46.6% of total revenues; and sales of handicrafts made up the remaining 2.9%.
For the 2014 first quarter, gross profit was $1.5 million, or 74.5% of total revenues, compared with $1.2 million, or 67.8% of total revenues for the comparable 2012 quarter. The increase in the gross profit margin was primarily attributable to higher gross profit margin in the yew trees segment.
Operating expenses decreased 39.7% to $167,000 for the quarter ended March 31, 2014, from $278,000 in the year-ago quarter.
Net income for the three-months ended March 31, 2014 increased 45.9% to $1.4 million from $942,000 in the same quarter last year. Due to an unrealized foreign currency translation loss of $258,000 for the first quarter of 2014, as compared to a gain of $155,000for the first quarter of 2013, comprehensive income for both the first quarter of 2014 and 2013 was approximately $1.1 million, or $0.02 per diluted share. The change reflects the effect of the value of the U.S. dollar in relation to the RMB.
“We are pleased to have recorded double digit growth across all three revenue categories, with TCM raw material sales volume increasing 14% to 6,070 kg in the quarter. While the number of Yew Trees sold decreased, we sold higher quality yew trees, which resulted in improved profitability,” said Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group. “As we move forward, we aim to drive further profitability by focusing on the sale of higher quality Yew Trees.”
ABOUT YEW BIO-PHARM GROUP, INC.
Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. To learn more, please visit http://www.yewbiopharm.com/.
This press release forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements involve a number of risks and uncertainties that could cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: our ability to collect from our largest customers; our dependence on a small number of customers for raw materials, including a related party; our ability to continue to purchase raw materials at relatively stable prices; our dependence on a small number of customers for our yew trees for reforestation; our ability to market successfully raw materials used in the manufacture of traditional Chinese medicines; and our ability to receive continued preferential tax treatment for the sale of yew trees and potted yew trees. From time to time, these risks, uncertainties and other factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its most recent annual report on Form 10-K. Yew Bio does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise, except as required under applicable law.